Buy-And-Bill A Bust For Novartis's Leqvio?
Executive Summary
The US commercial strategy for the PCSK9 inhibitor Leqvio was tied to reimbursement under Medicare Part B, but it hasn't developed the way Novartis envisioned.
You may also be interested in...
Alnylam/Roche’s Zilebesiran Affirms Efficacy, But Commercially Relevant Data Await
The KARDIA-1 monotherapy study was successful, but KARDIA-2 will give a better sense of the market opportunity.
Novartis Gets Expansion For Earlier Use Of Leqvio
Leqvio was approved by the US FDA for a broad label for high cholesterol in patients with an increased risk of heart disease, expanding beyond the initial approval for patients with ASCVD.
Two Cardiovascular Trial Hits Get Merck & Co.’s Blood Pumping
Merck has taken two important steps towards its goal of achieving eight new cardiovascular drug approvals by 2030, presenting promising data for two potential blockbusters at the ACC meeting.